Economic evaluation using decision analytical modelling : design, conduct, analysis, and reporting by Petrou, Stavros & Gray, Alastair
 University of Warwick institutional repository: http://go.warwick.ac.uk/wrap 
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information. 
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s):  Petrou, S. and Gray, A. 
Article Title: Economic evaluation using decision analytical 
modelling : design, conduct, analysis, and reporting 
Year of publication: 2011 
Link to published article:  
http://dx.doi.org/10.1136/bmj.d1766 
Publisher statement: © Petrou, S. and Gray, A. (2011). Economic 
evaluation using decision analytical modelling : design, conduct, 
analysis, and reporting. BMJ, 342, pp. d1766-1. This is an open-
access article distributed under the terms of the Creative Commons 
Attribution Non-commercial License, which permits use, distribution, 
and reproduction in any medium, provided the original work is properly 
cited. 
Economic evaluation using decision analytical
modelling: design, conduct, analysis, and reporting
Evidence relating to healthcare decisions often comes from more than one study. Decision analytical
modelling can be used as a basis for economic evaluations in these situations.
Stavros Petrou professor of health economics 1, Alastair Gray professor of health economics 2
1Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK; 2Health Economics Research Centre, Department of
Public Health, University of Oxford, Oxford, UK
Economic evaluations are increasingly conducted alongside
randomised controlled trials, providing researchers with
individual patient data to estimate cost effectiveness.1However,
randomised trials do not always provide a sufficient basis for
economic evaluations used to inform regulatory and
reimbursement decisions. For example, a single trial might not
compare all the available options, provide evidence on all
relevant inputs, or be conducted over a long enough time to
capture differences in economic outcomes (or even measure
those outcomes).2 In addition, reliance on a single trial may
mean ignoring evidence from other trials, meta-analyses, and
observational studies. Under these circumstances, decision
analytical modelling provides an alternative framework for
economic evaluation.
Decision analytical modelling compares the expected costs and
consequences of decision options by synthesising information
from multiple sources and applying mathematical techniques,
usually with computer software. The aim is to provide decision
makers with the best available evidence to reach a decision—for
example, should a new drug be adopted? Following on from
our article on trial based economic evaluations,1 we outline
issues relating to the design, conduct, analysis, and reporting
of economic evaluations using decision analytical modelling.
Defining the question
The first stage in the development of any model is to specify
the question or decision problem. It is important to define all
relevant options available for evaluation, the recipient
population, and the geographical location and setting in which
the options are being delivered.3 The requirements of the
decision makers should have a crucial role in identifying the
appropriate perspective of the analysis, the time horizon, the
relevant outcome measures, and, more broadly, the scope or
boundaries of the model.4 If these factors are unclear, or different
decision makers have conflicting requirements, the perspective
and scope should be broad enough to allow the results to be
disaggregated in different ways.5
Decision trees
The simplest form of decision analytical modelling in economic
evaluation is the decision tree. Alternative options are
represented by a series of pathways or branches as in figure 1,
which examines whether it is cost effective to screen for breast
cancer every two years compared with not screening. The first
point in the tree, the decision node (drawn as a square) represents
this decision question. In this instance only two options are
represented, but additional options could easily be added. The
pathways that follow each option represent a series of logically
ordered alternative events, denoted by branches emanating from
chance nodes (circular symbols). The alternatives at each chance
node must be mutually exclusive and their probabilities should
sum exactly to one. The end points of each pathway are denoted
by terminal nodes (triangular symbols) to which values or
pay-offs, such as costs, life years, or quality adjusted life years
(QALYs), are assigned. Once the probabilities and pay-offs
have been entered, the decision tree is “averaged out” and
“folded back” (or rolled back), allowing the expected values of
each option to be calculated.4
Decision trees are valued for their simplicity and transparency,
and they can be an excellent way of clarifying the options of
interest. However, they are limited by the lack of any explicit
time variable, making it difficult to deal with time dependent
elements of an economic evaluation.6 Recursion or looping
within the decision tree is also not allowed, so that trees
representing chronic diseases with recurring events can be
complex with numerous lengthy pathways.
Markov models
An alternative form of modelling is the Markov model. Unlike
decision trees, which represent sequences of events as a large
number of potentially complex pathways,Markovmodels permit
a more straightforward and flexible sequencing of outcomes,
including recurring outcomes, through time. Patients are
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Glossary of terms
Cost effectiveness acceptability curve—Graphical depiction of the probability that a health intervention is cost effective
across a range of willingness to pay thresholds held by decision makers for the health outcome of interest
Cost effectiveness plane—Graphical depiction of difference in effectiveness between the new treatment and the
comparator against the difference in cost
Discounting—The practice of reducing future costs and health outcomes to present values
Health utilities—Preference based outcomes normally represented on a scale where 0 represents death and 1 represents
perfect health
Incremental cost effectiveness ratio—A measure of cost effectiveness of a health intervention compared with an
alternative, defined as the difference in costs divided by the difference in effects
Multiparameter evidence synthesis—A generalisation of meta-analysis in which multiple variables are estimated jointly
Quality adjusted life year (QALY)—Preference-based measure of health outcome that combines length of life and health
related quality of life (utility scores) in a single metric
Time horizon—The start and end points (in time) over which the costs and consequences of a health intervention will
be measured and valued
Value of information analysis—An approach for estimating the monetary value associated with collecting additional
information within economic evaluation
assumed to reside in one of a finite number of health states at
any point in time and make transitions between those health
states over a series of discrete time intervals or cycles.3 6 The
probability of staying in a state or moving to another one in
each cycle is determined by a set of defined transition
probabilities. The definition and number of health states and
the duration of the cycles will be governed by the decision
problem: one study of treatment for gastro-oesophageal reflux
disease used one month cycles to capture treatment switches
and side effects,7 whereas an analysis of cervical cancer
screening used six monthly cycles to model lifetime outcomes.8
Figure 2 presents a state transition diagram and matrix of
transition probabilities for a Markov model of a hypothetical
breast cancer intervention. There are three health states: well,
recurrence of breast cancer, and dead. In this example, the
probability of moving from the well state at time t to the
recurrence state at time t+1 is 0.3, while the probability of
moving from well to dead is 0.1. At each cycle the sum of the
transition probabilities out of a health state (the row
probabilities) must equal 1. In order for the Markov process to
end, some termination condition must be set. This could be a
specified number of cycles, a proportion passing through or
accumulating in a particular state, or the entire population
reaching a state that cannot be left (in our example, dead); this
is called an absorbing state.
An important limitation of Markov models is the assumption
that the transition probabilities depend only on the current health
state, independent of historical experience (the Markovian
assumption). In our example, the probability of a person dying
from breast cancer is independent of the number of past
recurrences and also independent of how long the person spent
in the well state before moving to the recurrent state. This
limitation can be overcome by introducing temporary states that
patients can only enter for one cycle or by a series of temporary
states that must be visited in a fixed sequence.4
The final stage is to assign values to each health state, typically
costs and health utilities.6 9 Most commonly, such models
simulate the transition of a hypothetical cohort of individuals
through the Markov model over time, allowing the analyst to
estimate expected costs and outcomes. This simply involves,
for each cycle, summing costs and outcomes across health states,
weighted by the proportion of the cohort expected to be in each
state, and then summing across cycles.3 If the time horizon of
the model is over one year, discounting is usually applied to
generate the present values of expected costs and outcomes.1
Alternative modelling approaches
AlthoughMarkovmodels alone or in combination with decision
trees are the most common models used in economic
evaluations, other approaches are available.
Patient level simulation (or microsimulation) models the
progression of individuals rather than hypothetical cohorts. The
models track the progression of potentially heterogeneous
individuals with the accumulating history of each individual
determining transitions, costs, and health outcomes.3 10 Unlike
Markov models, they can simulate the time to next event rather
than requiring equal length cycles and can also simulate multiple
events occurring in parallel.10
Discrete event simulations describe the progress of individuals
through healthcare processes or systems, affecting their
characteristics and outcomes over unrestricted time periods.10
Discrete event simulations are not restricted to the use of equal
time periods or the Markovian assumption and, unlike patient
level simulation models, also allow individuals to interact with
each other11—for example, in a transplant programme where
organs are scarce and transplant decisions and outcomes for any
individual affect everyone else in the queue.
Dynamic models allow internal feedback loops and time delays
that affect the behaviour of the entire health system or population
being studied. They are particularly valuable in studies of
infectious diseases, where analysts may need to account for the
evolving effects of factors such as herd immunity on the
likelihood of infection over time, and their results can differ
substantially from those obtained from static models.12
The choice of modelling approach will depend on various
factors, including the decision maker’s requirements.10 11 13
Identifying, synthesising, and
transforming data inputs
The process of identifying and synthesising evidence to populate
a decision analytical model should be consistent with the general
principles of evidence based medicine.3 14 These principles are
broadly established for clinical evidence.15 Less clear is the
strategy that should be adopted to identify and synthesise
evidence on other variables, such as costs and health utilities,
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other than it should be transparent and appropriate given the
objectives of the model.16 Indeed, many health economists
recognise that the time and resource constraints imposed by
many funders of health technology assessments will tend to
preclude systematic reviews of the evidence for all variables.17
If evidence is not available from randomised trials, it has to be
drawn from other sources, such as epidemiological or
observational studies, medical records, or, more controversially,
expert opinion. And sometimes the evidence from randomised
trials may not be appropriate for use in the model—for example,
cost data drawn from a trial might reflect protocol driven
resource use rather than usual practice18 or might not be
generalisable to the jurisdiction of interest.5 These
methodological considerations have increased interest in
multiparameter evidence synthesis (box)19 in decision analytical
modelling. These techniques acknowledge the importance of
trying to incorporate correlations between variables in models,
which may have an important influence on the resulting
estimates of cost effectiveness.2 However, accurately assessing
the correlation between different clinical events, or between
events and costs or health utilities, may be difficult without
patient level data from a single source. Another complication
is that evidence may have to be transformed in complex ways
to meet the requirements of the model—for example, interval
probabilities reported in the literature may have to be
transformed into instantaneous rates and then into transition
probabilities corresponding to the cycle length used in aMarkov
model.3 4 14
Quantifying and reporting cost
effectiveness
Once data on all variables required by the model have been
assembled, the model is run for each intervention being
evaluated in order to estimate its expected costs and expected
outcomes (or effects). The results are typically compared in
terms of incremental cost effectiveness ratios and depicted on
the cost effectiveness plane (box).1
Handling variability, uncertainty, and
heterogeneity
The results of a decision analytical model are subject to the
influences of variability, uncertainty, and heterogeneity, and
these must be handled appropriately if decision makers are to
be confident about the estimates of cost effectiveness.3 13
Variability reflects the randomness arising from the modelling
process itself—that is, the fact that models typically use random
numbers when determining whether an event with a given
probability of occurring happens or not in any given cycle or
model run, so that an identical patient will experience different
outcomes each time they proceed through the model. This
variability, sometimes referred to as Monte Carlo uncertainty,
is not informative and needs to be eliminated by running the
model repeatedly until a stable estimate of the central tendency
has been obtained.20 There is little evidence or agreement on
how many model runs are needed to eliminate such variability,
but it may be many thousands.
Parameter uncertainty reflects the uncertainty and imprecision
surrounding the value of model variables such as transition
probabilities, costs, and health utilities. Standard sensitivity
analysis, in which each variable is varied separately and
independently, does not give a complete picture of the effects
of joint uncertainty and correlation between variables.6
Probabilistic sensitivity analysis, in which all variables are
varied simultaneously using probability distributions informed
by estimates of the sample mean and sampling error from the
best available evidence, is therefore the preferred way of
assessing parameter uncertainty.13 Probabilistic sensitivity
analysis is usually executed by running the model several
thousand times, each time varying the parameter values across
the specified distributions and recording the outputs—for
example, costs and effects—until a distribution has been built
up and confidence intervals can be estimated. Probabilistic
sensitivity analysis also allows the analyst to present cost
effectiveness acceptability curves, which show the probability
that each intervention is cost effective at an assumed maximum
willingness to pay for health gains.21 If a model has been derived
from a single dataset, bootstrapping can be used to model
uncertainty—that is, repeatedly re-estimating the model using
random subsamples drawn with replacement from the full
sample.22
Structural or model uncertainty reflects the uncertainty
surrounding the structure of the model and the assumptions
underpinning it—for example, the way a disease pathway is
modelled. Such model uncertainty is usually examined with a
sensitivity analysis, re-running the model with alternative
structural assumptions.6 Alternatively, several research groups
could model the same decision problem in different ways and
then compare their results in an agreed way. This approach has
been used extensively in fields such as climate change but less
commonly in health economics. However, one example is
provided by the Mount Hood Challenge, which invited eight
diabetes modelling groups to independently predict clinical trial
outcomes on the basis of changes in risk factors and then
compare their predictions.23 How the results from different
models can be reconciled in the absence of a gold standard is
unclear; however, Bojke and colleagues have recommended
some form of model averaging, whereby each model’s results
could be weighted by a measure of model adequacy.24
Finally, heterogeneity should be clearly differentiated from
variability because it reflects differences in outcomes or in cost
effectiveness that can in principle be explained by variations
between subgroups of patients, either in terms of baseline
characteristics such as age, risk level, or disease severity or in
terms of both baseline characteristics and relative treatment
effects. As in the analysis of clinical trials, subgroups should
be predefined and carefully justified in terms of their clinical
and economic relevance.25 A model can then be re-run for
different subgroups of patients.
Alternatively, heterogeneity can be addressed by making model
variables functions of other variables—for example, transition
probabilities between events or health states might be
transformed into functions of age or disease severity. As with
subgroup analysis in clinical trials, care must be taken to avoid
generating apparently large differences in cost effectiveness
that are not based on genuine evidence of heterogeneity. For
example, Mihaylova et al, recognising the absence of evidence
of heterogeneity in treatment effect across subgroups in the
Heart Protection Study, applied the same relative risk reduction
to different subgroups defined in terms of absolute risk levels
at baseline, resulting in large but reliable differences in cost
effectiveness.26 27
Model evaluation
Evaluation is an important, and often overlooked, step in the
development of a decision analytical model. Well evaluated
models are more likely to be believed by decision makers. Three
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steps in model validation of escalating difficulty are face
validation, internal validation, and external validation:
Face or descriptive validation entails checking whether the
assumptions and structure of a model are reliable, sensible, and
can be explained intuitively.14This may also require experiments
to assess whether setting some variables at null or extreme
values generates predictable effects on model outputs.
Internal validation requires thorough internal testing of the
model—for example by getting an independent researcher or
using different software to construct a replicate of the model
and assess whether the results are consistent.14 28 Internal
validation of a model derived from a single data source, for
example a Markov model being used to simulate long term
outcomes beyond the end of a clinical trial, may involve proving
that the model’s predicted results also fit the observed data used
in the estimation.22 In these circumstances some analysts also
favour splitting the initial data in two and using one set to “train”
or estimate the model and the other to test or validate the model.
Some analysts also calibrate the model, adjusting variables to
ensure that the results accord with aggregate and observable
outcomes, such as overall survival.29 This approach has been
criticised as an ad hoc search for values that makes it impossible
to characterise the uncertainty in the model correctly.30
External validation assesses whether the model’s predictions
match the observed results in a population or over a time period
that was not used to construct the model. This might entail
assessingwhether themodel can accurately predict future events.
For example, the Mount Hood Challenge compared the
predictions of the diabetes models with each other and the
reported trial outcomes.23 External validation might also be
appropriate for calibrated models.
Value of additional research
Decision analytical models are increasingly used as a framework
for indicating the need for and value of additional research. We
have established that the analyst will never be certain that the
value placed on each variable is correct. As a result, there are
distributions surrounding the outputs of decision analytical
models that can be estimated using probabilistic sensitivity
analysis and synthesised using cost effectiveness acceptability
curves.6 These techniques indicate the probability that the
decision to adopt an intervention on grounds of cost
effectiveness is correct. The techniques also allow a
quantification of the cost of making an incorrect decision, which
when combined with the probability of making an incorrect
decision generates the expected cost of uncertainty. This has
become synonymous with the expected value of perfect
information (EVPI)—that is, the monetary value associated
with eliminating the possibility of making an incorrect decision
by eliminating parameter uncertainty in the model.31 A
population-wide EVPI can be estimated by multiplying the
EVPI estimate produced by a decision analytical model by the
number of decisions expected to be made on the basis of the
additional information.32 This can then be compared with the
potential costs of further research to determine whether further
studies are economically worthwhile.33 34 The approach has been
extended in the form of expected value of partial perfect
information (EVPPI), which estimates the value of obtaining
perfect information on a subset of parameters in the model, and
the expected value of sample information (EVSI), which focuses
on optimal study design issues such as the optimal sample size
of further studies.3
Conclusions
Further detail on the design, conduct, analysis, and reporting of
economic evaluations using decision analytical modelling is
available elsewhere.4 6This article and our accompanying article1
show that there is considerable overlap betweenmodelling based
and trial based economic evaluations, not only in their objectives
but, for example, in dealing with heterogeneity and presenting
results, and in both cases we have argued the benefits of using
individual patient data. These two broad approaches should be
viewed as complements rather than as competing alternatives.
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Figures
Fig 1 Decision tree for breast cancer screening options4
Fig 2Markov state diagram and transition probability matrix for hypothetical breast cancer intervention. The arrows represent
possible transitions between the three health states (well, recurrence, and dead), loops indicate the possibility of remaining
in a health state in successive cycles, and the dashed line indicates the possibility of backwards transition from recurrence
of breast cancer to the well state after successful treatment. The cycle length is set at one year
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